Our History

A long-established and proven track record

The origins of the Acino – which was named “Schweizerhall” until 2008 – date back to 1836 when the company was founded around a saltworks operation near Basle. Subsequently, the company widened its activities to become both a manufacturer and trader and enlarged its portfolio with value added products including chemical specialties such as feeding stuffs, fertilizers and active pharmaceutical ingredients.

In 1994, the company went public on the Swiss stock exchange (SIX: ACIN) and gradually streamlined its business to focus on chemicals, pharmaceuticals and biotechnology. The subsequent years saw a focusing of the company’s activities on advanced drug delivery with the acquisition of Cimex Pharma AG, a Swiss supplier of complex solid oral dosage forms, in 2004, and of Novosis AG, Europe’s second largest manufacturer of transdermal patches and of biodegradable implants, in 2006.

  • 1992

    The Biovac institute started

  • 2008

    Change of the group and subsidiaries name to Acino

  • 1998

    Biovac Holdings sold 40% stake to Litha Investment Group

  • 2011

    Acquisition of combined Middle East and African Business of Cephalon Acquisition of Mepha’s production and R&D facilities and the business in MEA, LATAM and Asia. Commercialization of products under the brand “Acino Switzerland”

  • 2003

    Biovac Consortium awarded contract with SA goverment in forming a PPP The Biovac Institute

  • 2013

    Takeover by Avista Capital and Nordic Capital – Acino is delisted from the stock exchange

  • 2006

    Litha Investments purchase extra 11% of Biovac Holdings

    Name Changes to Litha Healthcare Holdings (LHH)

  • 2014

    Acquisition of Copharm in Russia

  • 2009

    Completed funding and planning for Biovac vaccine manufacturing site CT

  • 2015

    Acquisition of PharmaStart in Ukraine

  • 2010

    Litha Healthcare Group Lists on JSE

  • 2016

    Move of the Headquarters to Zurich and start of a substantial re-organization in Switzerland

    In–licensing agreement for the combination painkiller Maxigesic of AFT

    Acquisition of MENA operations and product rights of Norgine B.V.

    Aquisition of Takeda’s manufacturing plant in Põlva, Estonia

  • 2011

    International NDB signed with Cpoint Capital Inc.

    Biovac extends FSA with DOH to 2016

    LHG acquires Goldex Healthcare and OTC Pharma SA

  • 2012

    LHG purchases 100% of Pharmaplan for R590 m and merges business with Litha Pharma Division

    Paladin Labs Inc. acquires 44.5% of LHG

  • 2013

    Endo International plc, offers to 100% of majority shareholder Paladin Labs Inc.

  • 2014

    March 2014
    Endo International plc, completes acquisition pf Paladin Labs Inc. effectively owing 65% of Litha Healthcare Group Limited

    October 2014
    Endo and LHG announce intent to acquire balance of Litha shares

  • 2015

    February 2015
    Endo International plc, completes 100% acquisition of Litha Healthcare Group Limited. Litha delists from JSE

    June 2015
    Litha Healthcare Group changes to (Pty) Ltd.

    August 2015
    Litha announces divestment of medical and vaccine business

    October 2015
    Endo completes acquisition of Aspen product portfolio


    The story continues